Join the Oncology Voice Network. Join for Free
How to Develop IDPs Individual Development Plans and Road Maps for Career Development
Field Medical Excellence Individual Development Plans Career Growth for MSLs Professional Development Activities Medical Affairs Mentorship

How to Develop IDPs Individual Development Plans and Road Maps for Career Development


Share This Article


Summary

In this episode, Tom Caravela is joined by Elaine Nadeau to delve into the realm of field medical excellence and the significance of Individual Development Plans (IDPs). Elaine shares her career journey and transition into this field, highlighting the role of IDPs in fostering career growth. The discussion covers how to initiate an IDP, the process of crafting one, and examples of professional development activities. The episode emphasizes the manager's role and mentorship, distinguishing IDPs from performance reviews, and maintaining their relevance, especially during COVID. Elaine offers valuable advice for MSLs on professional growth, concluding with encouraging words and a call to subscribe.

My guest today is Elaine Nadeau, Director Field Excellence at EMD Serono. We discuss how MSLs can Develop IDPs (Individual Development Plans) and Road Maps for Career Development. 

In this episode we discuss:

  • Who is Elaine and what she does
  • How she got into the medical affairs
  • Her role in Field Medical Excellence
  • What is IDP and its importance
  • MSLs starting on their own IDP
  • The timeframe in creating the plan
  • The pre-work and self-reflection of IDP
  • Examples of professional development activities
  • The manager’s involvement and role
  • The different contributions of a coach versus a mentor
  • New skills mandatory for MSLs during COVID
  • Elaine’s advice for MSLs and MSL Leaders as we look to the future

Click for Source
Field Medical Excellence, Individual Development Plans, Career Growth for MSLs, Professional Development Activities, Medical Affairs Mentorship

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Demystifying and Unpacking Omnichannel Engagement
Partner Avatar MSL Talk: Tom Caravela, Donnie Wooten

Demystifying and Unpacking Omnichannel Engagement

Podcast
Gratitude: An absolute MUST for career advancement
Partner Avatar MSL Talk: Tom Caravela

Gratitude: An absolute MUST for career advancement

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN